Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 3.98B 589M 512M 475M 438M 825M 56.24B 840M 5.63B 2.2B 27.93B 2.21B 2.16B 93.93B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.84B 716M 622M 578M 533M 1B 68.38B 1.02B 6.84B 2.68B 33.96B 2.69B 2.63B 114B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
29/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
03/07/25 Realcan Pharmaceutical Vice President Detained MT
02/07/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
03/06/25 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
03/06/25 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day-1.09%
1 week+1.50%
Current month+10.16%
1 month+7.54%
3 months-16.62%
6 months-20.29%
Current year-15.84%
1 week 2.59
Extreme 2.59
2.8
1 month 2.44
Extreme 2.44
2.89
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 25/04/2021
President 61 25/05/2023
Corporate Officer/Principal 40 29/10/2019
Director TitleAgeSince
Chairman 61 20/11/2009
Director/Board Member 43 20/11/2009
Chairman 48 07/10/2019
Date Insider Type Main position Quantity % Market Cap.
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+1.50%-12.58%-23.66% 595M
-1.64%+4.97%+21.06%+115.08% 104B
+2.13%+0.56%+43.92%+148.44% 53.66B
-0.67%+2.42%+2.78%+279.49% 23.74B
+0.96%+0.06%-12.34%-18.96% 8.24B
+0.82%-4.25%-34.50%-35.47% 7.58B
-0.28%+3.88%-9.11%-24.89% 7.04B
-0.47%-1.96%+17.46%+27.60% 6.19B
-0.79%-2.18%-0.45%+24.27% 5.36B
-2.02%+4.51%+21.24%+24.95% 3.83B
Average -0.62%+3.34%+3.75%+51.68% 22.03B
Weighted average by Cap. -1.50%+5.98%+19.82%+119.65%

Financials

2024 2025
Net sales 7.97B 1.18B 1.02B 950M 876M 1.65B 112B 1.68B 11.25B 4.4B 55.85B 4.42B 4.33B 188B 7.3B 1.08B 937M 870M 803M 1.51B 103B 1.54B 10.3B 4.03B 51.15B 4.05B 3.96B 172B
Net income 20.62M 3.05M 2.65M 2.46M 2.27M 4.27M 291M 4.35M 29.12M 11.4M 145M 11.45M 11.2M 486M 16.07M 2.38M 2.06M 1.92M 1.77M 3.33M 227M 3.39M 22.69M 8.89M 113M 8.92M 8.73M 379M
Net Debt 1.6B 236M 205M 190M 175M 331M 22.52B 337M 2.25B 882M 11.19B 886M 866M 37.61B 860M 127M 110M 103M 94.63M 178M 12.14B 181M 1.21B 476M 6.03B 478M 467M 20.28B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
29/07/26 CN¥2.710 -1.09% 30,267,230
29/07/26 CN¥2.740 +0.74% 25,963,570
28/07/26 CN¥2.720 -0.37% 21,598,853
27/07/26 CN¥2.730 +4.60% 32,663,500
24/07/26 CN¥2.610 -4.04% 25,727,800
  1. Stock Market
  2. Stocks
  3. 002589 Stock